Journey Strategic Wealth LLC Has $685,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Journey Strategic Wealth LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 19.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,962 shares of the company’s stock after selling 1,862 shares during the quarter. Journey Strategic Wealth LLC’s holdings in Novo Nordisk A/S were worth $685,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in NVO. Natixis Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the period. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $86,000. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $4,066,000. Finally, Zions Bancorporation N.A. increased its holdings in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.2 %

NVO opened at $84.36 on Monday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm has a market capitalization of $378.56 billion, a PE ratio of 27.30, a P/E/G ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company’s 50-day moving average is $93.56 and its 200 day moving average is $113.03.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.